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Abstract Sensitivity of CD95-mediated apoptosis has been
reported to vary during cell cycle progression (FEBS Lett. (1997)
412, 91^93). Here, we report that three human glioma cell lines
with different p53 status (i) undergo growth arrest and
synchronous cell cycle re-entry after prolonged serum depriva-
tion, (ii) do not exhibit cell cycle-related changes in CD95
expression at the cell surface, and (iii) do not exhibit cell cycle-
related changes in susceptibility to DC95 ligand-induced
apoptosis. In contrast, cell cycle-specific activity was demon-
strated for various cancer chemotherapy drugs. Further, CD95
expression and susceptibility to CD95 ligand-induced apoptosis
does not vary during cell cycle progression of Jurkat T cells,
HeLa cervical carcinoma and HepG2 hepatocellular carcinoma
cells. These results do not support a role for the cell cycle phase
as an important predictor of vulnerability to CD95-mediated
apoptosis.
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1. Introduction
CD95 ligand (CD95L) is a cytokine of the nerve growth
factor/tumor necrosis factor family that induces apoptosis in
susceptible target cells. The death signalling pathway triggered
by CD95 involves activation of caspases 8 and 3 and does not
require new mRNA or protein synthesis. Although the cell
cycle-associated p34cdc2 kinase may be required for CD95-
mediated apoptosis [1,2], no direct links between cell cycle
progression and CD95-mediated apoptosis have been noted.
However, a recent report in this Journal suggested that ago-
nistic CD95 antibodies killed WIL-2 B lymphoma cells in a
cell cycle-speci¢c fashion with preferential killing in G0/1 [3].
A related observation had previously been made by other
authors [4]. Moreover, CD95-mediated apoptosis was re-
ported to involve translocation of p53 from the cytoplasma
to the nucleus [3]. These unexpected ¢ndings prompted us to
reevaluate the role of cell cycle progression in CD95-mediated
apoptosis of various glioma and non-glial tumor cell lines.
2. Materials and methods
All chemical reagents, vincristine, doxorubicin, taxol, cisplatin and
camptothecin were from Sigma (St. Louis, MO), 1-[(4-amino-2-meth-
yl-5-pyrimidinyl)methyl]-3-(2-chloroethyl)-3-nitrosourea (ACNU) and
teniposide (VM26) from Bristol (Munich, Germany). Soluble CD95L
was obtained from CD95L cDNA-transfected N2A neuroblastoma
cells. T98G human glioma, HeLa human cervical carcinoma,
HepG2 human hepatocellular and Jurkat human T cells were from
ATCC (Rockville, MD). LN-18 and LN-229 human glioma cells were
kindly provided by Dr. N. de Tribolet (Lausanne, Switzerland) [5].
The glioma cells were cultured as described [6]. Cell cycle analysis was
performed using ethidium bromide staining of ethanol-permeabilized
cells. CD95 expression was monitored by £ow cytometry [7]. Survival
was measured by crystal violet assay [6].
3. Results and discussion
We compared serum deprivation and several pharmacolog-
ical approaches for their ability to induce a stable, but rever-
sible, cell cycle arrest in human malignant glioma cell lines.
Aphidicolin (10 WM) and hydroxyurea (650 WM) induced a G1
arrest within 24 h but most cells did not survive a recovery
period for 24 h after drug withdrawal. Nocodazole (0.1 WM)
induced a G2 arrest within 24 h but, again, most cells died
after a recovery period of 24 h. Deferoxamin (500 WM) and
mimosine (300 WM) did not lead to a cell cycle arrest at 40 h
but were toxic. In contrast, serum deprivation of LN-18, LN-
229 and T98G cells for 60 h reliably induced a cell cycle arrest
in G0/1 without signi¢cant cell loss. Reexposure to serum-
containing medium induced synchronous cell cycle re-entry
without cytotoxicity, unlike the release from cell cycle block,
e.g. induced by nocodazole (Fig. 1A, B).
We then asked whether the glioma cells exhibited changes
in CD95 expression at the cell surface during cell cycle pro-
gression which might account for a preferential vulnerability
to CD95-mediated cytotoxicity at speci¢c phases of the cell
cycle. This was not the case. There was no signi¢cant modu-
lation of the SFI value, which indicates the signal ratio of the
speci¢c antibody versus an isotype control antibody upon
£ow cytometric analysis of CD95 expression [7] in either cell
line (Fig. 1C). Next, we examined whether the exposure to
CD95L for 4 or 8 h resulted in di¡erential e¡ects either in
acute cytotoxicity assays or in clonogenic cell death studies,
depending on the cell cycle phase. Again, there was no prom-
inent di¡erence in CD95L-induced cytotoxic or clonogenic
cell death in either cell line (Fig. 1D). Since the negative
data obtained for CD95 expression and sensitivity to
CD95L-induced apoptosis might have been cell type-speci¢c,
we performed experiments corresponding to those of Fig. 1B^
D in three more human cancer cell lines of di¡erent histoge-
netic origin, Jurkat T cells, HepG2 hepatocellular carcinoma
and HeLa cervical carcinoma cells. To induce S phase exit and
loss of [3H]thymidine incorporation, Jurkat cells were serum-
deprived for 48 h, and HepG2 and HeLa cells for 60 h. Cell
cycle arrest in these cell lines was less complete than in the
glioma cell lines, and cell cycle re-entry most synchronous in
HepG2 cells. Similar to the glioma cells, there was no signi¢-
cant change in either CD95 expression or susceptibility to
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CD95L-induced apoptosis in either of these cell lines after cell
cycle re-entry, as assessed at 10 h, 20 h, or 27 h after reexpo-
sure to serum-containing medium, compared with non-
synchronized or serum-deprived cells (data not shown). We
therefore only summarize the baseline data for the cell lines
studied here (Table 1).
To con¢rm that di¡erential sensitivity during cell cycle pro-
gression can be detected using our experimental set-up, we
also examined possible cell cycle-speci¢c actions of various
cancer chemotherapy drugs in the three glioma cell lines
(Fig. 1E). Camptothecin, vincristine, VM26, taxol and cispla-
tin were more active when administered during S phase.
Small, but insigni¢cant, di¡erences between sensitivity in
G0/1 and S phase were detected for ACNU or doxorubicin.
G0/1 cells did not di¡er signi¢cantly in sensitivity from non-
synchronized cells but were more resistant to chemotherapy
than serum-deprived cells (data not shown).
Since changes in p53 function were hypothesized to play a
role in cell cycle-dependent modulation of CD95-mediated
apoptosis, we included cell lines which are wild-type (LN-
229) or mutant (LN-18, T98G) for p53 [5]. Thus, the p53
status had no impact on the lack of cell cycle dependency of
CD95-mediated apoptosis in our cell lines. This is also con-
sistent with the observation that CD95-mediated apoptosis,
e.g. during activation-induced T cell death, is not blocked or
enhanced in p53 knockout mice [8]. We also note that in the
preceding study [3], the cells were most resistant to CD95-
mediated apoptosis, immediately after the thymidine block
(G1/S) and most sensitive 9 h later (G1), even though most
cells are in G1 in both populations. Therefore, we hypothe-
sized that thymidine might have had a direct impact on
CD95-mediated apoptosis that was unrelated to cell cycle pro-
gression. However, we were not able to delineate any e¡ect of
thymidine on CD95-mediated apoptosis of glioma cells (data
not shown). Taken together, cell cycle progression had no
impact on CD95 expression or sensitivity to CD95L-induced
apoptosis in three human malignant glioma cell lines and
three other cancer cell lines of di¡ering histogenetic origin
(Jurkat, HepG2, HeLa) in this study.
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Fig. 1. The sensitivity of human glioma cells to CD95-mediated
apoptosis is not modulated during cell cycle progression. A: LN-
229 cells were maintained in serum-free medium for 60 h and then
reexposed to serum-containing medium. Cell cycle analysis was per-
formed at 10 h, 20 h or 27 h. B: Percentages of LN-229 cells in
G0/1 (open squares), G2/M (¢lled circles) or S (¢lled triangles,
dashed lines) were measured using ModFit LT 2.0 (Verity Software,
Topsham, MN, USA). Similar data were obtained in LN-18 and
T98G cells (data not shown). C: LN-18 cells were either not
synchronized, or serum-deprived for 60 h, or serum-deprived and
subsequently restimulated with serum-containing medium for 10 h
or 27 h. CD95 expression was monitored by £ow cytometry as de-
scribed [7]. Open pro¢les correspond to the signal obtained with an
isotype control antibody, black pro¢les to those obtained with the
speci¢c CD95 antibody. D: LN-229 cells were not synchronized, or
serum-deprived for 60 h (0 h), or serum-deprived and restimulated
with serum-containing medium, and exposed to CD95L, for 4 h, at
10 h, 20 h, or 27 h after restimulation, and further cultured for 48
h (two generation times) in fresh medium. Data are expressed as
mean percentages and S.E.M. of survival (n = 3, Ps 0.05, t-test). E:
LN-229 cells were serum-deprived for 60 h, restimulated with se-
rum-containing medium for 10 h (open bars) or 20 h (¢lled bars),
then exposed to the drugs (50 WM ACNU, 0.8 WM camptothecin
(CPT), 0.4 WM vincristine (VCR), 5 WM VM26, 0.4 WM doxorubicin
(DXR), 0.4 WM taxol (TAX), 20 WM cisplatin (CPL)) for 4 h, and
further cultured for 48 h (two generation times) in fresh medium.
Data are expressed as in D (*P6 0.05).
Table 1
CD95 expression and susceptibility to CD95L-induced apoptosis in
non-synchronized non-glial cancer cell lines
CD95 expression Survival (%) Survival (%)
(SFI) CD95L (20 U/ml) CD95L (80 U/ml)
Jurkat 3.0 þ 0.3 34 þ 2 26 þ 3
HepG2 2.8 þ 0.1 86 þ 3 60 þ 3
HeLa 2.0 þ 0.2 76 þ 4 43 þ 3
CD95 expression was assessed by £ow cytometry, survival by crystal
violet staining after a 4 h pulse exposure to CD95L (20 or 80 U/ml)
and recovery of 48 h (for details, see Section 2).
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